Stäfa (Switzerland), February 6, 2023 – Sonova Holding AG, a leading provider of hearing care solutions, announces today that its Audiological Care business has launched the SilentCloud™* medical app. The app offers a combination of therapies, making it a powerful tool for self-paced tinnitus management. It is part of an expanded portfolio of holistic hearing care services which supports Sonova’s innovation of the consumer journey.
Sonova offers a range of services adjacent to hearing aid fitting. These provide additional value for consumers by addressing different medical needs which often co-exist with hearing loss.1 One common symptom associated with hearing loss is tinnitus. With the SilentCloud app, Sonova provides a user-centered digital tool for tinnitus self-management which consolidates a range of proven therapies recommended in international clinical guidelines.2
Tinnitus affects 10% to 15% of the adult population and 20% of those affected experience it as bothersome, or even debilitating, requiring clinical intervention.3 Four out of five people with tinnitus also experience some degree of hearing loss.4
Even though there is currently no cure for it, many approaches can relieve the burden of tinnitus. Recommendations for tinnitus management include Cognitive Behavioral Therapy3 that can be combined with sound therapies, education, and counseling.
“SilentCloud is a subscription-based medical app which will empower patients to manage their tinnitus symptoms from the comfort of their own home while being guided by one of our trained hearing care experts,“ says Christophe Fond, Group Vice President Audiological Care at Sonova. “By providing options for managing a co-existing medical need, the app will support Sonova’s strategic goal to reach more people with hearing loss and to engage with them earlier in their hearing care journey.”
All content offered in SilentCloud consists of validated approaches for tinnitus management.2 The app is currently available in Belgium and Italy and can be downloaded on the App Store® or on Google Play™. A roll-out in more countries will follow later this year. For more information, watch the SilentCloud video here.
1Besser, J., Stropahl, M., Urry, E., Launer, S. (2018). Comorbidities of hearing loss and the implications of multimorbidity for audiological care. Hearing research, 369, 3-14.
2Please consult https://www.lapperre.be/nl/tinnitus/silentcloud/bibliotheek/ if you are interested in further information regarding supporting evidence for SilentCloud.
3Cima, R., Mazurek, B., Haider, H., Kikidis, D., Lapira, A., Noreña, A., & Hoare, D. J. (2019). A multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment. HNO, 67(Suppl 1), 10–42. https://doi.org/10.1007/s00106-019-0633-7
4Baguley, D., McFerran, D., & Hall, D. (2013). Tinnitus. The Lancet, 382, 1600-1607. doi:10.1016/S0140-6736(13)60142-7
*SilentCloudTM is registered in the European Union, Switzerland and the United Kingdom.
App Store is a trademark of Apple Inc., registered in the U.S. and other countries.
Google Play and the Google Play logo are trademarks of Google LLC.
Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova’s control. Should one or more of these risks or un-certainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
About Sonova
Sonova is a global leader in innovative hearing care solutions: from personal audio devices and wireless communication systems to audiological care services, hearing aids and cochlear implants. The Group was founded in 1947 and is headquartered in Stäfa, Switzerland.
Sonova operates through four businesses – Hearing Instruments, Audiological Care, Consumer Hearing and Cochlear Implants – and the core brands Phonak, Unitron, AudioNova, Sennheiser (under license) and Advanced Bionics as well as recognized regional brands. The Group’s globally diversified sales and distribution channels serve an ever growing consumer base in more than 100 countries.
In the 2021/22 financial year, the Group generated sales of CHF 3.4 billion, with a net profit of CHF 664 million. Over 17,000 employees are working on achieving Sonova’s vision of a world where everyone enjoys the delight of hearing.
For more information please visit www.sonova.com
